Cargando…
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
OBJECTIVE: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with l...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073780/ https://www.ncbi.nlm.nih.gov/pubmed/32201595 http://dx.doi.org/10.1136/lupus-2019-000360 |
_version_ | 1783506696855879680 |
---|---|
author | Arriens, Cristina Aberle, Teresa Carthen, Fredonna Kamp, Stan Thanou, Aikaterini Chakravarty, Eliza James, Judith A Merrill, Joan T Ogunsanya, Motolani E |
author_facet | Arriens, Cristina Aberle, Teresa Carthen, Fredonna Kamp, Stan Thanou, Aikaterini Chakravarty, Eliza James, Judith A Merrill, Joan T Ogunsanya, Motolani E |
author_sort | Arriens, Cristina |
collection | PubMed |
description | OBJECTIVE: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with lupus about clinical trial participation. METHODS: A qualitative research design employed three 90 min focus groups led by a trained moderator and guided by the Theory of Planned Behaviour. Open-ended questions about trial participation included advantages and disadvantages (behavioural beliefs), approving and disapproving significant others (normative beliefs), and participation enhancers and barriers (control beliefs). Discussions were recorded, transcribed and analysed to identify emerging themes. RESULTS: Patients with SLE (n=23) aged 21–72, with increased proportion of minority groups (65%), participated. Reported advantages of trial participation included altruism and personal benefit. Disadvantages included uncertainties, disappointment, information burden, and life–health balance. Although some patients had discussed research participation with approving or disapproving family or friends, self-approval superseded external approval. Barriers included logistics and time, and facilitators included flexibility in scheduling, advance notice of studies, streamlined forms, and hope for SLE improvement. CONCLUSIONS: Knowledge about potential benefits of clinical trial participation was high. Minority patients demonstrated confidence in making their own informed decisions, but major barriers for all participants included burdensome forms, travel, childcare, and work. These suggest a major impact on minority and all recruitment from behavioural and control aspects, which should be considered in the logistics of trial design. This does not minimise the potential importance of improved access and education about clinical research. |
format | Online Article Text |
id | pubmed-7073780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70737802020-03-20 Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers Arriens, Cristina Aberle, Teresa Carthen, Fredonna Kamp, Stan Thanou, Aikaterini Chakravarty, Eliza James, Judith A Merrill, Joan T Ogunsanya, Motolani E Lupus Sci Med Clinical Trials and Drug Discovery OBJECTIVE: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with lupus about clinical trial participation. METHODS: A qualitative research design employed three 90 min focus groups led by a trained moderator and guided by the Theory of Planned Behaviour. Open-ended questions about trial participation included advantages and disadvantages (behavioural beliefs), approving and disapproving significant others (normative beliefs), and participation enhancers and barriers (control beliefs). Discussions were recorded, transcribed and analysed to identify emerging themes. RESULTS: Patients with SLE (n=23) aged 21–72, with increased proportion of minority groups (65%), participated. Reported advantages of trial participation included altruism and personal benefit. Disadvantages included uncertainties, disappointment, information burden, and life–health balance. Although some patients had discussed research participation with approving or disapproving family or friends, self-approval superseded external approval. Barriers included logistics and time, and facilitators included flexibility in scheduling, advance notice of studies, streamlined forms, and hope for SLE improvement. CONCLUSIONS: Knowledge about potential benefits of clinical trial participation was high. Minority patients demonstrated confidence in making their own informed decisions, but major barriers for all participants included burdensome forms, travel, childcare, and work. These suggest a major impact on minority and all recruitment from behavioural and control aspects, which should be considered in the logistics of trial design. This does not minimise the potential importance of improved access and education about clinical research. BMJ Publishing Group 2020-03-15 /pmc/articles/PMC7073780/ /pubmed/32201595 http://dx.doi.org/10.1136/lupus-2019-000360 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Clinical Trials and Drug Discovery Arriens, Cristina Aberle, Teresa Carthen, Fredonna Kamp, Stan Thanou, Aikaterini Chakravarty, Eliza James, Judith A Merrill, Joan T Ogunsanya, Motolani E Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
title | Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
title_full | Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
title_fullStr | Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
title_full_unstemmed | Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
title_short | Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
title_sort | lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
topic | Clinical Trials and Drug Discovery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073780/ https://www.ncbi.nlm.nih.gov/pubmed/32201595 http://dx.doi.org/10.1136/lupus-2019-000360 |
work_keys_str_mv | AT arrienscristina lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT aberleteresa lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT carthenfredonna lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT kampstan lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT thanouaikaterini lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT chakravartyeliza lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT jamesjuditha lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT merrilljoant lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers AT ogunsanyamotolanie lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers |